Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.
作者信息
Willett Brian J, Grove Joe, MacLean Oscar A, Wilkie Craig, De Lorenzo Giuditta, Furnon Wilhelm, Cantoni Diego, Scott Sam, Logan Nicola, Ashraf Shirin, Manali Maria, Szemiel Agnieszka, Cowton Vanessa, Vink Elen, Harvey William T, Davis Chris, Asamaphan Patawee, Smollett Katherine, Tong Lily, Orton Richard, Hughes Joseph, Holland Poppy, Silva Vanessa, Pascall David J, Puxty Kathryn, da Silva Filipe Ana, Yebra Gonzalo, Shaaban Sharif, Holden Matthew T G, Pinto Rute Maria, Gunson Rory, Templeton Kate, Murcia Pablo R, Patel Arvind H, Klenerman Paul, Dunachie Susanna, Haughney John, Robertson David L, Palmarini Massimo, Ray Surajit, Thomson Emma C
机构信息
MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.
School of Mathematics & Statistics, University of Glasgow, Glasgow, UK.
出版信息
Nat Microbiol. 2022 Oct;7(10):1709. doi: 10.1038/s41564-022-01241-6.
Abstract
摘要
相似文献
1
Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.出版商更正：严重急性呼吸综合征冠状病毒2型奥密克戎变异株是一种具有改变的细胞进入途径的免疫逃逸变异株。
Nat Microbiol. 2022 Oct;7(10):1709. doi: 10.1038/s41564-022-01241-6.
2
SARS-CoV-2 Omicron subvariants progressively adapt to human cells with altered host cell entry.SARS-CoV-2 奥密克戎亚变种逐渐适应宿主细胞进入机制改变的人类细胞。
mSphere. 2024 Sep 25;9(9):e0033824. doi: 10.1128/msphere.00338-24. Epub 2024 Aug 27.
3
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.疫苗、治疗性抗体和病毒进入抑制剂的敏感性以及应对 SARS-CoV-2 奥密克戎变异株的进展。
Clin Microbiol Rev. 2022 Sep 21;35(3):e0001422. doi: 10.1128/cmr.00014-22. Epub 2022 Jun 6.
4
Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents.武汉新冠肺炎康复者血清对 SARS-CoV-2 奥密克戎变异株的中和能力急剧下降。
Emerg Microbes Infect. 2022 Dec;11(1):567-572. doi: 10.1080/22221751.2022.2031311.
5
Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors.模拟 SARS-CoV-2 奥密克戎变异株中 Cathepsin B/L 的增加和 TMPRSS2 用于细胞进入的减少如何影响 TMPRSS2 和 Cathepsin B/L 抑制剂的疗效和协同作用。
J Theor Biol. 2023 Sep 7;572:111568. doi: 10.1016/j.jtbi.2023.111568. Epub 2023 Jun 30.
6
Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron.描述 SARS-CoV-2 刺突蛋白 E484 表位中暂时固定突变引起的固有和有效适应性变化，并鉴定变异株奥密克戎中 E484A 进化的上位条件。
Virol J. 2023 Nov 8;20(1):257. doi: 10.1186/s12985-023-02154-4.
7
Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities.深入了解严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变体的免疫逃逸可能性及不依赖变体的潜在治疗机会。
Heliyon. 2023 Feb;9(2):e13285. doi: 10.1016/j.heliyon.2023.e13285. Epub 2023 Jan 31.
8
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.SARS-CoV-2 奥密克戎是一种具有改变的细胞进入途径的免疫逃逸变体。
Nat Microbiol. 2022 Aug;7(8):1161-1179. doi: 10.1038/s41564-022-01143-7. Epub 2022 Jul 7.
9
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells.与德尔塔变异株相比，SARS-CoV-2 奥密克戎变异株在表达 TMPRSS2 的细胞中的复制和融合活性较低。
Emerg Microbes Infect. 2022 Dec;11(1):277-283. doi: 10.1080/22221751.2021.2023329.
10
The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant.SARS-CoV-2 德尔塔-奥密克戎重组谱系（XD）表现出与奥密克戎（BA.1）变体相似的免疫逃逸特性。
Int J Mol Sci. 2022 Nov 14;23(22):14057. doi: 10.3390/ijms232214057.
引用本文的文献
1
Enhanced reverse zoonotic potential and immune evasion by omicron JN.1 variant.奥密克戎JN.1变体增强的反向人畜共患病潜力和免疫逃逸能力。
iScience. 2025 Jun 6;28(7):112824. doi: 10.1016/j.isci.2025.112824. eCollection 2025 Jul 18.
2
Characterising COVID-19 school and childcare outbreaks in Canada in 2021: a surveillance study.2021年加拿大新冠病毒疾病学校及托儿机构疫情特征：一项监测研究
BMJ Public Health. 2024 Jan 8;2(1):e000248. doi: 10.1136/bmjph-2023-000248. eCollection 2024 Jun.
3
Induction of Superior Systemic and Mucosal Protective Immunity to SARS-CoV-2 by Nasal Administration of a VSV-ΔG-Spike Vaccine.通过鼻内接种VSV-ΔG-刺突疫苗诱导对SARS-CoV-2的全身和黏膜保护性免疫
Vaccines (Basel). 2024 May 1;12(5):491. doi: 10.3390/vaccines12050491.
4
Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells.区分 SARS-CoV-2 奥密克戎亚变种对人肺上皮细胞的细胞进入潜力。
Viruses. 2024 Mar 1;16(3):391. doi: 10.3390/v16030391.
5
Investigating the Antibody Imprinting Hypothesis among Canadian Paramedics after SARS-CoV-2 Omicron Variant Circulation.调查 SARS-CoV-2 奥密克戎变异株流行后加拿大护理人员中的抗体印迹假说。
Immunohorizons. 2024 Feb 1;8(2):193-197. doi: 10.4049/immunohorizons.2400010.
6
The association between COVID-19 vaccination and confirmed patients with hospitalization in Omicron era: A retrospective study.奥密克戎时代 COVID-19 疫苗接种与住院确诊患者之间的关联：一项回顾性研究。
Medicine (Baltimore). 2023 Dec 29;102(52):e36777. doi: 10.1097/MD.0000000000036777.
7
Spatiotemporal evolution of SARS-CoV-2 in the Bangkok metropolitan region, Thailand, 2020-2022: implications for future outbreak preparedness.2020-2022 年泰国曼谷大都市区 SARS-CoV-2 的时空演变：对未来疫情爆发准备的启示。
Microb Genom. 2023 Dec;9(12). doi: 10.1099/mgen.0.001170.
8
Long-term immune response to Omicron-specific mRNA vaccination in mice, hamsters, and nonhuman primates.小鼠、仓鼠和非人灵长类动物对奥密克戎特异性mRNA疫苗的长期免疫反应。
MedComm (2020). 2023 Dec 15;4(6):e460. doi: 10.1002/mco2.460. eCollection 2023 Dec.
9
COVID-19 infection and efficacy of vaccination in patients with rheumatic diseases during Omicron outbreak in South Korea: a prospective cohort study.韩国奥密克戎疫情期间风湿性疾病患者的 COVID-19 感染和疫苗效力：一项前瞻性队列研究。
RMD Open. 2023 Nov;9(4). doi: 10.1136/rmdopen-2023-003398.
10
Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity, and neutralization sensitivity.SARS-CoV-2 奥密克戎刺突蛋白 S2 亚基的突变强烈影响其构象、融合性和中和敏感性。
J Virol. 2023 Nov 30;97(11):e0092223. doi: 10.1128/jvi.00922-23. Epub 2023 Oct 20.
Zotero 插件